"Eduardo Vilar-Sanchez has spent more than 10 years pursuing a goal that seemed very distant, but which he now sees as a little closer: to develop a preventive vaccine against cancer. The physician and researcher is leading a study that presented the first promising results of a colon cancer vaccine in a small group of patients suffering from a rare disease that makes them 17 times more likely to develop colon cancer than the general population."
"The trial focuses on a very small and specific population: patients with Lynch syndrome. This inherited genetic disorder affects approximately one in 270 people and significantly increases their risk of developing recurrent colon cancer throughout their lives. The trial involved 45 patients with this syndrome who, at the time, had not developed colon cancer, but did have potentially precancerous lesions known as polyps."
The trial tested Nous-209, an inactivated monkey adenovirus carrying 209 tumor-associated antigens, in 45 patients with Lynch syndrome who had precancerous polyps but no colon cancer. One year after vaccination, existing precancerous lesions did not grow and no new lesions appeared. The vaccine was well tolerated with no serious treatment-related adverse events reported. Immune activation against multiple tumor antigens was observed, suggesting the vaccine can prime immune recognition of cancer cells. The findings support feasibility of preventive cancer vaccination for high-risk populations, while longer follow-up and larger trials are needed to confirm clinical benefit.
Read at english.elpais.com
Unable to calculate read time
Collection
[
|
...
]